Matt Willis

We are pleased to announce that AAH have been awarded a new reduced wholesale distribution contract for LEO Pharma. From 1st September, the entire portfolio including dermatology and critical care products will be available through AAH. #Pharmacy #Healthcare

99

The HCPC renewal window for Biomedical Scientists opens on 1st September 2025 and will remain open until 30th November 2025. Renewal is essential to maintain your HCPC registration and continue practising as a Biomedical Scientist. Renewing your registration early helps ensure a smooth process and avoids last-minute stress. 👉 Read the IBMS update for full details: https://bit.ly/47UFJFC

65

3 Comments

We’re delighted to launch our new 2-week eLearning course, Metallo-β-Lactamase (MBL) Infections: Diagnosis and Management. With MBL-producing pathogens emerging as a global public health threat, this course is designed to build knowledge on their burden, epidemiology, resistance mechanisms, and risk factors. On this course, you’ll explore diagnostic challenges, clinical presentations, and case studies, gaining the skills and confidence to support timely diagnosis and effective management while contributing to improved patient outcomes and antimicrobial stewardship. https://lnkd.in/ee5anKRG

73

2 Comments

💉 Big changes ahead for Scotland’s cosmetic industry. The Scottish Government is set to be the first UK nation to introduce detailed regulation of non-surgical cosmetic procedures. 📝 Healthcare partners Duncan Batchelor and Claire Raftery explore what this means for practitioners and patient safety in The Scotsman: https://bit.ly/45VV876

45

"This [low-GWP] transition means two things. First, it means having the new propellant available and providing our partners with the medication formulation support needed. Second, it means ensuring the old propellant remains available as long as the market needs it, recognising that the speed of transition varies around the world". International Pharmaceutical Industry magazine (IPI) spoke recently to Markus Laubscher, Head of Orbia Fluor & Energy Materials' Pharma Business Unit.  While the discussion covered various topics, it was centered around the innovations in low-GWP propellants and how this impacts the topic of sustainability within the respiratory pharmaceutical industry, amidst one of the biggest transitions this industry has ever seen. Read the full article: https://lnkd.in/e_ScVeED #Orbia #Zephex30years #LowGWPPropellant #Zephex #HFA152a

40

Our Gastroenterology colleagues have successfully introduced another biosimilar medicine (Ustekinumab) for the treatment of patients with Inflammatory Bowel Disease (IBD), as part of ongoing efforts to enhance care and improve value for the NHS. This is the third biosimilar product to be implemented at OUH for IBD, which includes long-term conditions such as Crohn’s disease and ulcerative colitis. The move is part of a nationally-supported approach to safely and effectively expand the use of biosimilar medicines across the NHS. Biosimilars are highly similar versions of already approved biological medicines. They are assessed and authorised according to the same rigorous standards of pharmaceutical quality, safety, and clinical effectiveness that apply to all biological treatments. The move to Ustekinumab, along with previous biosimilar switches, has saved the Trust an estimated £4.9 million – funds which can be reinvested into patient care and service improvements. The changeover to the biosimilar was carefully planned, with the pharmacy team, IBD specialist nurses, and consultant team all integral to the process, and colleagues ensured there was careful communication with and support for affected patients. Those patients who had additional questions or concerns were offered appointments in ad-hoc clinics, where they could discuss the change directly with a consultant and specialist pharmacist. 🗣️ Dr Oliver Brain, Consultant Gastroenterologist at OUH, said: “Good disease control is vital in managing inflammatory bowel disease, and we are pleased to have introduced this additional treatment option safely and smoothly. Biosimilars offer the same clinical benefits as the originator drug, while helping us make best use of NHS resources.” Thank you to all involved – you can read more in our news story ⬇️ 🔗 https://orlo.uk/kJ4cK

56

1 Comment

Since the start of this year, major changes to tariffs on international trade have come into force.   Customs delays due to incomplete paperwork or incorrect payments could result in irreversible damage to valuable treatments, so it is essential to stay ahead of these changes. Here at Biocair, our team proactively monitors and manages regulatory shifts to ensure shipments transit smoothly. To learn more about the complexities and implications of tariff changes, take a look at our guidance: https://hubs.li/Q03D6hX60

27

1 Comment